Check-Cap - CHEK Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CHEK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHEK, but not buy additional shares or sell existing shares.
View CHEK analyst ratings or view top-rated stocks.

Check-Cap's stock was trading at $2.20 at the start of the year. Since then, CHEK shares have decreased by 40.0% and is now trading at $1.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 6th 2023.
View our CHEK earnings forecast.

Check-Cap Ltd. (NASDAQ:CHEK) released its quarterly earnings results on Wednesday, November, 3rd. The medical research company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.20.

Check-Cap's stock reverse split before market open on Friday, November 25th 2022. The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Avinger (AVGR), Biocept (BIOC) and Purple Biotech (KTOV).

(CHEK) raised $13 million in an initial public offering (IPO) on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Check-Cap's stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.56%).

Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHEK stock can currently be purchased for approximately $1.32.

Check-Cap (NASDAQ:CHEK) has a market capitalization of $6.36 million. The medical research company earns $-17,200,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The official website for the company is www.check-cap.com. The medical research company can be reached via phone at 972546706451, via email at jeremy@lifesciadvisors.com, or via fax at 972-4821-1267.